

Securities Code: 4523

Materials and information provided in this financial disclosure may contain “forward-looking statements” based on current expectations, forecasts, estimates, business goals and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations.

Contents

1. Consolidated Statement of Income	-----	1
2. Capital Expenditures, Depreciation and Amortization	-----	2
3. Segment Information	-----	2
4. Financial Results by Reporting Segment	-----	3-----

1. Consolidated Statement of Income

	FY 2016							(billions of yen)		
	FY 2016							FY 2016		
Revenue	426.4	100.0	547.9	100.0	409.2	100.0	96.0	(17.2)	548.0	100.0
Cost of sales	149.3	35.0	194.5	35.5	147.9	36.1	99.0	(1.4)	199.0	36.3

2. Capital Expenditures, Depreciation and Amortization

(billions of yen)

Capital expenditures	14.3	19.8	26.5	12.2	34.0
Property, plant and equipment	8.8	12.8	8.2	(0.6)	13.0
Intangible assets	5.5	7.0	18.3	12.8	21.0
Depreciation and amortization	27.5	34.1	20.0	(7.5)	27.0
Property, plant and equipment	10.0	13.1	8.2	(1.8)	11.0
Intangible assets	17.5	21.0	11.7	(5.7)	16.0

*Capital expenditures are shown on an accrual basis

3. Segment Information

1) Revenue by Reporting Segment

(billions of yen)

					CER YOY (%)
Pharmaceutical Business Total	413.5	531.8	402.6	97.4	104.1
Japan Pharmaceutical Business	225.1	284.9	227.4	101.0	101.0
Americas Pharmaceutical Business	92.9	122.2	85.2	91.7	104.7
United States	91.9	121.0	84.1	91.5	104.4
China Pharmaceutical Business	38.2	49.3	36.4	95.3	115.0
Asia Pharmaceutical Business	26.0	34.0	25.6	98.5	113.2
EMEA Pharmaceutical Business	31.3	41.3	28.0	89.6	104.0
Other Business	13.0	16.2	6.6	51.1	55.0
Consolidated revenue	426.4	547.9	409.2	96.0	102.6

* Indicates revenue from external customers

* CER=Constant Exchange Rates

2) Profit by Reporting Segment

(billions of yen)

	FY 2015			FY 2016 YOY (%)	CER YOY (%)
	Q3 YTD	Fulu91 i0D	Fulu91 i0D		
Pharmaceutical Business Total	137.4	168.9	135.8	98.8	105.9
Japan Pharmaceutical Business	94.0	114.3	83.9	89.2	89.2
Americas Pharmaceutical Business	17.8	23.6	23.7	133.1	153.4
China Pharmaceutical Business	10.8	12.6	10.9	100.8	135.2
Asia Pharmaceutical Business	6.6	8.3	7.2	108.2	127.9
EMEA Pharmaceutical Business	8.2	10.2	10.2	124.1	138.1
Other Business	2.3	3.3	1.3	57.5	59.6
R&D Expenses	(91.4)	(122.3)	(79.5)	87.0	95.6
Group headquarters' management costs and other expenses	(7.8)	(13.0)	(9.4)	120.7	119.8
Gain from a bargain purchase	-	-	9.3	-	-
Gain on sale of subsidiaries	8.0	15.0	0.1	0.9	0.9
Consolidated operating profit	48.6	51.9	57.6	118.5	122.8

4. Financial Results by Reporting Segment

1) Japan Pharmaceutical Business

(billions of yen)

	FY 2015		Q3 YTD	YOY (%)
	Q3 YTD	Full year		
Revenue	225.1	284.9	227.4	101.0
Prescription medicines	185.5	233.9	191.4	103.2
Generics	21.1	28.5	20.8	98.6
Consumer Healthcare Business	14.1	18.1	15.2	107.7
Diagnostics	4.4	4.4	-	-
Segment profit	94.0	114.3	83.9	89.2

Japan prescription medicines - revenue from major products

Fully human anti-TNF- monoclonal antibody Humira	25.1	32.6	29.3	116.8
Alzheimer's disease / Dementia with Lewy bodies treatment Aricept	33.5	40.5	24.1	72.0
Pain treatment (neuropathic pain, fibromyalgia) Lyrica	18.8	24.7	18.4	98.1
Proton-pump inhibitor Pariet**	24.8	30.4	17.0	68.8
Peripheral neuropathy treatment Methycobal	16.5	20.8	14.4	87.1
Insomnia treatment Lunesta	4.6	6.0	6.1	132.7
Anticancer agent Halaven	5.3	6.8	6.0	112.8
Oral anticoagulant Warfarin	6.0	7.6	5.4	89.7
Elemental diet Elental**	-	-	5.1	-
Branched-chain amino acid preparation Livact**	-	-	5.1	-
Osteoporosis treatment Actonel	-	-	-	-

2) Americas Pharmaceutical Business (North, Central and South America)

(billions of yen)

	FY 2015		FY 2016	
	Q3 YTD	Full year	Q3 YTD	YOY (%)
Revenue	92.9	122.2	85.2	91.7 <104.7>
United States	91.9	121.0	84.1	91.5 <104.4>
Segment profit	17.8	23.6	23.7	133.1 <153.4>
Americas - revenue from major products				
Antiemetic agent Aloxi	41.8	54.7	35.5	85.0
United States	41.8	54.7	35.5	85.0
[Millions USD]	[343]	[455]	[333]	<97.0>
Anticancer agent Halaven	13.3	18.3	12.5	93.8
United States	12.7	17.5	11.9	93.4
[Millions USD]	[105]	[146]	[112]	<106.6>
Anticancer agent Lenvima	5.9	8.8	10.7	179.8
United States	5.9	8.8	10.6	178.6
[Millions USD]	[49]	[73]	[100]	<203.9>
Antiepileptic agent Banzel	9.9	13.2	9.9	100.2
United States	9.8	13.1	9.8	100.1
[Millions USD]	[80]	[109]	[92]	<114.3>
Proton-pump inhibitor AcipHex	6.7	8.3	5.5	82.3
[Millions USD]	[55]	[69]	[52]	<93.9>
Antiepileptic agent Fycompa	2.7	3.8	3.7	134.8
United States	2.6	3.7	3.5	134.9
[Millions USD]	[21]	[31]	[33]	<154.0>
Antiobesity agent BELVIQ	3.6	4.4	2.8	78.3
[Millions USD]	[29]	[37]	[26]	<89.3>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

* The U.S. is the only country in the Americas where Eisai directly markets AcipHex and BELVIQ

3) China Pharmaceutical Business

(billions of yen)

	FY 2015		FY 2016	
	Q3 YTD	Full year	Q3 YTD	YOY (%)
Revenue	38.2	49.3	36.4	95.3 <115.0>
Segment profit	10.8	12.6	10.9	100.8 <135.2>
China - revenue from major products				
Peripheral neuropathy treatment Methycobal	15.1 [Millions RMB] [785]	18.7 [993]	13.8 [865]	91.2 <110.2>
Liver disease / Allergic disease agents Stronger Neo-Minophagen C and Glycyron Tablets	7.0 [Millions RMB] [366]	9.3 [492]	6.2 [388]	87.8 <106.0>
Alzheimer's disease treatment Aricept	4.1 [Millions RMB] [213]	5.6 [295]	4.5 [281]	109.5 <132.2>
Proton pump inhibitor Pariet	2.4 [Millions RMB] [125]	3.3 [173]	2.8 [173]	114.4 <138.1>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

4) Asia Pharmaceutical Business (mainly South Korea, Taiwan, Hong Kong, India and ASEAN)

(billions of yen)

	FY 2015		FY 2016	
	Q3 YTD	Full year	Q3 YTD	YOY (%)
Revenue	26.0	34.0	25.6	98.5 <113.2>
Segment profit	6.6	8.3	7.2	108.2 <127.9>
Asia - revenue from major products				
Alzheimer's disease treatment Aricept	7.7	10.0	7.3	94.2 <108.3>
Fully human anti-TNF- monoclonal antibody Humira	6.8	9.0	7.0	103.1 <118.4>
Proton-pump inhibitor Pariet	2.7	3.5	2.6	98.7 <113.4>
Peripheral neuropathy treatment Methycobal	2.5	3.1	2.1	86.7 <100.6>
Anticancer agent Halaven	1.4	1.9	1.5	101.9 <118.1>
Antiepileptic agent Fycompa	0.0	0.1	0.3	724.6 <833.7>
Anticancer agent Lenvima	0.0	0.0	0.2	496.7 <568.3>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

5. Revenue from Major Products

1) Neurology Products

(billions of yen)

	FY 2015		FY 2016	
	Q3 YTD	Full year	Q3 YTD	YOY (%)
Neurology Total	141.8	179.7	122.3	86.3 <93.1>
Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)	51.6	63.3	37.3	72.3 <76.7>
Japan	33.5	40.5	24.1	72.0
China	4.1	5.6	4.5	109.5 <132.2>
Asia	7.7	10.0	7.3	94.2 <108.3>
Methycobal (Peripheral neuropathy treatment)	34.7	43.5	31.0	89.1 <98.4>
Japan	16.5	20.8	14.4	87.1
China	15.1	18.7	13.8	91.2 <110.2>
Asia	2.5	3.1	2.1	86.7 <100.6>
Lyrica (Pain treatment [neuropathic pain, fibromyalgia]) - Japan	18.8	24.7	18.4	98.1
Inovelon/Banzel (Antiepileptic agent)	11.8	15.8	11.6	98.2 <112.2>
Americas	9.9	13.2	9.9	100.2 <114.4>
EMEA	1.7	2.2	1.4	84.1 <99.2>
Fycompa (Antiepileptic agent)	5.4	7.6	7.4	137.8 <157.9>
Japan	-	-	0.3	-
Americas	2.7	3.8	3.7	134.8 <154.0>
Asia	0.0	0.1	0.3	724.6 <833.7>
EMEA	2.6	3.6	3.1	120.5 <140.4>
Lunesta (Insomnia treatment) - Japan	4.6	6.0	6.1	132.7
Zonegran (Antiepileptic agent)	7.5	9.2	4.3	57.4 <67.3>
EMEA	6.1	7.6	4.0	65.1 <76.2>
BELVIQ (Antiobesity agent) - United States	3.6	4.4	2.8	78.3 <89.3>
Zebinix (Antiepileptic agent) - EMEA	2.8	3.8	2.6	94.9 <109.4>
Other	1.1	1.3	0.8	78.8 <78.8>

* Year-on-year percentage: figures shown in angle brackets "< >" exclude the effects of foreign currency fluctuations.

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan and the Philippines.

* Co-promotion income has been booked as the revenue for Lyrica.

2) Oncology Products

	Q3 YTD	Full year	FY 2016 Q3 YTD	YOY (%)
Oncology Products Total	88.6	118.4	87.4	98.7 <111.2>
Aloxi (Antiemetic agent) - United States	41.8	54.7	35.5	85.0 <97.0>
Halaven (Anticancer agent)	30.1	40.2	28.4	94.3 <105.8>
Japan	5.3	6.8	6.0	112.8
Americas	13.3	18.3	12.5	93.8 <107.1>
Asia	1.4	1.9	1.5	101.9 <118.1>
EMEA	10.0	13.2	8.4	84.2 <98.5>
Lenvima (Anticancer agent)				

6. Revenue Forecasts by Reporting Segment (FY 2016)

(billions of yen)

	Q3 YTD	Full year	Q3 YTD	Full year (est.)
Japan	225.1	284.9	227.4	300.0
	185.5	233.9	191.4	254.0
	25.1	32.6	29.3	40.0
	33.5	40.5	24.1	29.0
	24.8	30.4	17.0	21.5
	16.5	20.8	14.4	18.5
	4.6	6.0	6.1	8.0
	5.3	6.8	6.0	8.0
EMEA38.0	6.0	7.6	5.4	7.0
	-	-	5.1	6.5
	-	-	5.1	6.0
	5.1	6.4	4.4	6.0
Generics	21.1	28.5	20.8	28.5
Consumer Healthcare Business - Japan	14.1	18.1	15.2	17.5
	8.7	11.1	9.9	11.0
Diagnostics	4.4	4.4	-	-
Americas	92.9	122.2	85.2	117.0
United States	91.9	121.0	84.1	113.5
China	38.2	49.3	36.4	48.0
Asia	26.0	34.0	25.6	33.5
EMEA	31.3	41.3	28.0	38.0
Other	13.0	16.2	6.6	11.5
Consolidated revenue	426.4	547.9	409.2	548.0
Global revenue from major products				
Aricept	51.6	63.3	37.3	46.0
	37.0	46.1	28.3	33.0
Halaven	30.1	40.2	28.4	43.5
	Japan	5.3	6.8	6.0
	Americas	13.3	18.3	12.5
	Asia	1.4	1.9	1.5
	EMEA	10.0	13.2	8.4
Lenvima	7.7	11.5	15.1	24.0
	Japan	1.1	1.5	2.1
	Americas	5.9	8.8	10.7
	Asia	0.0	0.0	0.2
	EMEA	0.6	1.1	2.1
Fycompa (excluding Japan)	5.4	7.6	7.1	12.0
	Americas	2.7	3.8	3.7
	Asia	0.0	0.1	0.3
	EMEA	2.6	3.6	3.1

7. Consolidated Statement of Comprehensive Income

	FY 2015		(billions of yen) FY 2016		
	Q3 YTD	Full year	Q3 YTD	YOY (%)	Diff.
Profit for the period	38.4	55.0	40.9	106.5	2.5
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Financial assets measured at fair value through other comprehensive income	5.1	1.6	0.3	5.2	(4.9)
Remeasurements of defined benefit plans	-	(6.8)	-	-	-
Subtotal	5.1	(5.2)	0.3	5.2	(4.9)
Items that may be reclassified subsequently to profit or loss					

8. Consolidated Statement of Cash Flows

(billions of yen)

	FY 2015	FY 2016	
	Q3 YTD	Q3 YTD	Diff.
Operating activities			
Profit before income taxes	47.5	57.1	9.5
Depreciation and amortization	27.5	20.0	(7.5)
Impairment losses	0.2	0.2	(0.0)
(Increase) decrease in working capital	4.5	(25.2)	(29.7)
Interest and dividends received	1.6	1.5	(0.1)
Interest paid	(2.9)	(2.0)	1.0
Income taxes paid	(7.1)	(10.8)	(3.8)
Income taxes refund	1.7	10.5	8.8
Other	(11.5)	(8.5)	2.9
Net cash from operating activities	61.5	42.6	(18.9)
Investing activities			
Purchases of property, plant and equipment (1)	(3.6)	(4.1)	(0.5)
Proceeds from sales of property, plant and equipment (2)	13.2	0.2	(12.9)
Purchases of intangible assets (3)	(31.6)	(5.2)	26.4
Net cash outflow on acquisition of subsidiaries (4)	(9.0)	-	9.0
Net cash inflow on acquisition of subsidiaries (5)	-	19.3	19.3
Net cash inflow on sale of subsidiaries (6)	12.4	6.5	(5.9)
<Capital expenditures (cash basis)> (1)+(2)+(3)+(4)+(5)+(6)	(1.86)	16.7	35.3
Purchases of financial assets	(12.4)	(9.2)	3.2
Proceeds from sales and redemption of financial assets	12.8	8.7	(4.1)
Payments of time deposits exceeding 3 months	(16.6)	(40.9)	(24.3)
Proceeds from redemption of time deposits exceeding 3 months	23.9	13.1	(10.8)
Other	(0.1)	0.1	0.2
Net cash from (used in) investing activities	(11.0)	(11.4)	(0.5)
Financing activities			
Net increase (decrease) in short-term borrowings	20.8	-	(20.8)
Proceeds from long-term borrowings	-	10.0	10.0
Redemption of bonds	(30.0)	-	30.0
Dividends paid	(42.9)	(42.9)	(0.0)
Other	0.0	(2.6)	(2.6)
Net cash from (used in) financing activities	(52.1)	(35.5)	16.5
Effect of exchange rate change on cash and cash equivalents	(1.8)	(2.5)	(0.7)
Net increase (decrease) in cash and cash equivalents	(3.4)	(6.9)	(3.5)
Cash and cash equivalents at beginning of year	173.3	179.3	6.0
Cash and cash equivalents at end of year	170.0	172.4	2.5
Free cash flow	42.9	59.3	16.5

* "Free cash flow" = "Net cash from operating activities" - "Capital expenditures (cash basis)"

Notes

Cash flow from investing activities:

Net cash inflow on acquisition of subsidiaries due to acquisition of EA Pharma Co., Ltd.
Net cash inflow on sales of subsidiaries due to transfer of Sannova Co., Ltd.

Cash flow from financing activities:

Proceeds from long-term borrowings

9. Consolidated Statement of Financial Position

<Assets>

(billions of yen)

	FY 2015		FY 2016			
	March 31, 2016	Ratio (%)	December 31, 2016	Ratio (%)	% change	Diff.
Assets						
Non-current assets						
Property, plant and equipment	104.6	10.7	102.3	9.8	97.8	(2.3)
Goodwill	174.9	18.0	180.6	17.4	103.3	5.7
Intangible assets	104.2	10.7	111.4	10.7	107.0	7.3
Other financial assets	43.8	4.5	56.5	5.4	128.9	12.6
Other assets	7.1	0.7	10.9	1.0	152.5	3.7
Deferred tax assets	91.6	9.4	90.4	8.7	98.7	(1.2)
Total non-current assets	526.2	54.0	552.1	53.1	104.9	25.9
Current assets						
Inventories	73.7	7.6	83.1	8.0	112.7	9.4
Trade and other receivables	147.7	15.2	183.8	17.7	124.5	36.1
Other financial assets	19.5	2.0	37.8	3.6	193.4	18.3
Other assets	20.3	2.1	11.3	1.1	55.6	(9.0)
Cash and cash equivalents	176.8	18.2	172.4	16.6	97.5	(4.4)
Subtotal	438.0	45.0	488.3	46.9	111.5	50.3
Assets held for sales	9.8	1.0				(9.8)
Total current assets	447.8	46.0	488.3	46.9	109.1	40.5
Total assets	974.0	100.0	1,040.4	100.0	106.8	66.4

Notes

Assets

Increase due to acquisition of EA Pharma Co., Ltd.

Decrease in assets held for sale due to transfer of Sannova Co., Ltd.

<Equity and Liabilities >

(billions of yen)

	March 31, 2016	Ratio (%)	December 31, 2016	Ratio (%)	% change	Diff.
Equity						
Equity attributable to owners of the parent						
Share capital	45.0	4.6	45.0	4.3	100.0	-
Capital surplus	58.2	6.0	77.6	7.5	133.3	19.4
Treasury shares	(36.2)	(3.7)	(36.2)	(3.5)	99.9	0.0
Retained earnings	395.0	40.6	390.9	37.6	99.0	(4.1)
Other components of equity	111.7	11.5	116.2	11.2	104.0	4.5
Total equity attributable to owners of the parent	573.7	58.9	593.5	57.0	103.5	19.8
Non-controlling interests	3.2	0.3	17.6	1.7	556.2	14.4
Total equity	576.8	59.2	611.1	58.7	105.9	34.3
Liabilities						
Non-current liabilities						
Borrowings	203.6	20.9	214.8	20.6	105.5	11.2
Other financial liabilities	3.2	0.3	2.7	0.3	83.8	(0.5)
Retirement benefit liabilities	13.2	1.4	13.5	1.3	102.5	0.3
Provisions	1.2	0.1	1.2	0.1	104.3	0.1
Other liabilities	21.0	2.2	23.9	2.3	113.9	2.9
Deferred tax liabilities	0.3	0.0	0.3	0.0	118.5	0.1
Total non-current liabilities	242.4	24.9	256.4	24.6	105.8	14.0
Current liabilities						
Trade and other payables	56.4	5.8	66.2	6.4	117.3	9.8
Other financial liabilities	4.2	0.4	7.4	0.7	175.4	3.2
Income tax payables	5.4	0.6	6.7	0.6	124.1	1.3
Provisions	11.1	1.1	15.2	1.5	136.8	4.1
Other liabilities	74.7	7.7	77.3	7.4	103.5	2.6
Subtotal	151.9	15.6	172.9	16.6	113.8	20.9
Liabilities directly associated with assets held for sale	2.8	0.3				(2.8)
Total current liabilities	154.7	15.9	172.9	16.6	111.7	18.2
Total liabilities	397.2	40.8	429.3	41.3	108.1	32.1
Total equity and liabilities	974.0	100.0	1,040.4	100.0	106.8	66.4

Notes

Eq

10. Changes in Quarterly Results

1) Income Statement

(billions of yen)

	FY 2015				FY 2016		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Revenue	139.2	136.3	150.9	121.5	136.9	133.0	139.3
Cost of sales	49.4	50.1	49.8	45.2	49.8	48.4	49.7
Gross profit	89.8	86.2	101.2	76.3	87.1	84.6	89.7
Selling, general and administrative expenses	49.9	46.5	49.5	46.9	43.7	43.3	45.9
Selling expenses	16.0	15.5	14.8	14.9	12.5	13.6	14.8
Personnel expenses	22.3	19.8	20.2	19.8	19.8	19.2	19.6
Administrative and other expenses	11.6	11.2	14.6	12.2	11.4	10.5	11.6
Research and development expenses	32.7	30.1	28.5	30.9	26.2	28.8	24.6
Other income	0.4	1.5	8.3	7.4	10.3	0.8	1.2
Other expenses	0.0	0.6	0.8	2.6	1.7	0.6	1.4
Operating profit	7.6	10.5	30.6	3.3	25.8	12.8	19.0
Financial income	0.7	0.3	0.6	0.4	0.7	0.2	0.6
Financial costs	0.8	0.9	1.0	0.7	0.7	0.7	0.7
Profit before income taxes	7.4	9.9	30.2	3.0	25.8	12.3	18.9
Income taxes	1.9	4.3	2.9	(13.7)	4.9	3.6	7.6
Profit for the period	5.5	5.6	27.3	16.6	20.9	8.7	11.4
Attributable to							
Owners of the parent	5.4	5.6	27.3	16.6	19.7	8.2	10.5
Non-controlling interests	0.1	0.0	(0.0)	0.0	1.2	0.5	0.8
Comprehensive income for the period	20.2	(9.9)	30.5	(24.3)	(23.0)	2.0	66.7
Earnings per share (EPS, yen)	19.1	19.5	95.5	58.1	69.0	28.6	3.67

* From this fiscal year, the breakdown of selling, general and administrative expenses has been rearranged. The figures for the previous fiscal year have been revised and restated to reflect this change.

2) Capital Expenditures, Depreciation and Amortization

(billions of yen)

	FY 2015				FY 2016		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Capital expenditures	1.3	2.0	11.0	5.5	17.1	3.6	5.8
Property, plant and equipment	1.0	1.5	6.3	4.0	4.7	1.1	2.3
Intangible assets	0.3	0.5	4.7	1.5	12.4	2.5	3.5
Depreciation and amortization	10.3	10.1	7.0	6.6	8.0	5.9	6.1
Property, plant and equipment	3.5	3.3	3.2	3.1	2.9	2.7	2.7
Intangible assets	6.8	6.9	3.8	3.5	5.1	3.2	3.5

* Capital expenditures are shown on an accrual basis

3) Cash Flows

(billions of yen)

	FY 2015				FY 2016		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Cash flow from operating activities	21.1	22.7	17.7	34.1	(4.8)	31.6	15.8
Cash flow from investing activities	(17.4)	4.0	2.5	4.3	23.4	(10.3)	(24.5)
Cash flow from financing activities	(42.5)	(0.0)	(9.6)	(20.9)	(14.7)	(0.1)	(20.7)
Cash and cash equivalents at the end of period	138.7	160.1	170.0	179.3	172.7	190.8	172.4
Free cash flow	(10.3)	33.6	19.6	38.2	18.7	28.6	12.1

* "Free cash flow" = "Net cash from operating activities" - "Capital expenditures (cash basis)"

4) Financial Positions

(billions of yen)

	June 30, 2015	September 30, 2015	December 31, 2015	March 31, 2016	June 30, 2016	September 30, 2016	December 31, 2016
Total assets	1,001.7	987.1	1,018.2	974.0	963.1	965.2	1,040.4
Equity	599.7	590.0	600.6	576.8	562.7	564.9	611.1
Attributable to owners of the parent	596.3	586.7	597.3	573.7	545.9	547.7	593.5
Liabilities	402.0	397.1	417.6	397.2	400.4	400.3	429.3
Borrowings	217.0	216.3	227.0	203.6	210.7	210.1	214.8
Ratio of equity attributable to owners of the parent (%)	59.5	59.4	58.7	58.9	56.7	56.7	57.0
Liabilities ratio (Net DER / times)	0.11	0.06	0.06	0.01	0.04	(0.01)	(0.01)

* "Liabilities ratio (Net DER)" = ("Interest-bearing debt" ("Bonds and borrowings") - "Cash and cash equivalents" - "Time deposits exceeding three months, etc.") / "Equity attributable to owners of the parent"

5) Changes in Quarterly Revenue from Major Products

(1) Neurology Products

(billions of yen)

	FY 2015				FY 2016		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Neurology Total	46.8	45.6	49.5	37.9	40.6	39.4	42.3
Aricept (Alzheimer's disease / Dementia with Lewy bodies treatment)	18.0	16.0	17.6	11.7	13.2	11.9	12.2
Japan	11.4	10.1	12.0	7.0	8.9	7.5	7.7
China	1.4	1.4	1.4	1.5	1.4	1.5	1.6
Asia	2.6	2.5	2.6	2.3	2.4	2.4	2.5
Methycobal (Peripheral neuropathy treatment)	11.8	11.2	11.8	8.8	9.8	10.3	10.8
Japan	5.5	5.0	5.9	4.3	5.0	4.6	4.8
China	5.1	5.2	4.8	3.6	4.0	4.8	5.0
Asia	0.9	0.9	0.7	0.6	0.7	0.7	0.8
Lyrica (Pain treatment [neuropathic pain, fibromyalgia]) - Japan	5.7	6.1	6.9	6.0	6.1	5.8	6.5
Inovelon/Banzel (Antiepileptic agent)	3.4	4.0	4.5	4.0	3.7	3.8	4.1
Americas	2.7	3.3	3.8	3.4	3.1	3.3	3.5
EMEA	0.5	0.5	0.6	0.5	0.5	0.5	0.5
Fycompa (Antiepileptic agent)	1.5	1.8	2.2	2.2	2.5	2.3	2.7
Japan					0.1	0.1	0.1
Americas	0.7	0.9	1.1	1.1	1.2	1.1	1.4
Asia	0.0	0.0	0.0	0.1	0.1	0.1	0.1
EMEA	0.7	0.8	1.0	1.0	1.1	1.0	1.0
Lunesta (Insomnia treatment) - Japan	1.4	1.5	1.7	1.4	1.9	1.9	2.3
Zonegran (Antiepileptic agent)	2.4	2.6	2.5	1.6	1.6	1.4	1.3
EMEA	2.0	2.0	2.1	1.5	1.5	1.3	1.2
BELVIQ (Antiobesity agent) - United States	1.5	1.1	1.0	0.9	1.0	0.7	1.1
Zebinix (Antiepileptic agent) - EMEA	0.9	1.0	0.9	1.1	0.7	1.0	0.9
Other	0.3	0.3	0.4	0.3	0.3	0.3	0.3

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan and the Philippines.

* Co-promotion income has been booked as the revenue for Lyrica.

(2) Oncology Products

(billions of yen)

	FY 2015				FY 2016		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Oncology Total	27.9	29.5	31.2	29.8	28.5	29.4	29.5
Aloxi (Antiemetic agent) - Americas	13.5	14.1	14.2	12.9	12.0	12.1	11.4
Halaven (Anticancer agent)	10.1	9.8	10.2	10.1	9.4	9.3	9.7
Japan	1.8	1.6	1.8	1.5	2.0	2.0	2.0
Americas	4.4	4.6	4.4	5.0	4.2	4.1	4.2
Asia	0.4	0.5	0.5	0.5	0.5	0.5	0.5
EMEA	3.4	3.2	3.4	3.2	2.7	2.6	3.1
Lenvima (Anticancer agent)	1.3	2.8	3.6	3.8	4.4	5.2	5.5
Japan	0.2	0.4	0.5	0.5	0.7	0.7	0.7
Americas	1.1	2.2	2.7	2.9	3.2	3.7	3.8
Asia	-	-	0.0	(0.0)	0.0	0.1	0.1
EMEA	0.0	0.2	0.4	0.5	0.4	0.8	0.9
Treakisym/Symbenda (Anticancer agent)	1.1	1.0	1.2	0.9	1.1	1.1	1.1
Other	2.0	1.8	2.0	2.1	1.6	1.8	1.8

11. Major R&D Pipeline

In-House R&D Pipeline List

Product Name / Development Code	Additional Indication, etc.**	Development Stage***	Therapeutic Area****
---------------------------------	-------------------------------	----------------------	----------------------

New Approval

- Halaven (Lipo)

(1) Neurology

Development Code: **E2020** Generic Name: **donepezil** Product Name: **Aricept**

Indications / Drug class: Treatment for Alzheimer's disease / dementia with Lewy bodies

In-house

Development Code: **APD356** Generic Name: **lorcaserin** Product Name: **BELVIQ**

Indications / Drug class: Anti-obesity agent / serotonin 2C receptor agonist		In-license (Arena Pharmaceuticals)	
Description: Anti-obesity agent with novel mechanism of action. By selectively activating serotonin 2C receptors in the brain, it is believed to decrease food consumption and promote satiety. Approved in the United States by the U.S. Food and Drug Administration in June 2012 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m ² or greater (obese) or 27 kg/m ² or greater (overweight) in the presence of at least one weight-related comorbid condition. Launched in the United States in June 2013 after receiving a final scheduling designation from the U.S. Drug Enforcement Administration (DEA). Approved in Mexico in July 2016 and Brazil in December 2016.			
<input type="radio"/>	Obesity once-daily formulation (Additional Formulation)	US: approved (July 2016)	Oral
	Obesity	JP: PI	Oral

Development Code: **E2027**

Alzheimer's disease	US: PI	In-house	Oral
---------------------	--------	----------	------

Development Code: **E2730**

<input checked="" type="radio"/> Epilepsy	US: PI	In-house	Oral
---	--------	----------	------

Development progress from April 2016 onwards Development progress from October 2016 onwards

(2) Oncology

Development Code: **E7389** Generic Name: **eribulin** Product Name: **Halaven**

Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor		In-house	
Description: A synthetic analog of halichondrin B derived from the marine sponge, <i>Halichondria okadai</i> . Shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Approved in over 60 countries including in the United States, in Europe, Japan and Asia for use in chemotherapy for breast cancer. Approved in countries including the United States, Japan and in Europe for use in the treatment of soft tissue sarcoma.			
<input type="radio"/>		Study 304	CN: submitted (July 2016) Inj.
<input type="radio"/>		309	EU: approved (May 2016, for liposarcoma) Inj.
		302	JP/US/EU/AS: PIII Inj.
	Bladder cancer (Additional Indication)	702	US/EU: PI/II Inj.

Development progress from April 2016 onwards Development progress from October 2016 onwards

○ Development progress from April 2016 onwards © Development progress from October 2016 onwards

Reference Data [R&D Pipeline] 21

February 2, 2017 / Eisai Co., Ltd.

Development Code: **H3B-6527**

<input type="radio"/> Hepatocellular carcinoma	US: PI	In-house	Oral
--	--------	----------	------

Development Code: **H3B-8800**

<input type="radio"/> Blood cancer	US/EU: PI	In-house	Oral
------------------------------------	-----------	----------	------

Development Code: **E7438**

<input type="radio"/> Non-Hodgkin B-cell lymphoma	JP: PI	In-license (Epizyme, Inc.)	Oral
---	--------	----------------------------	------

(3) Gastrointestinal Disorders

Development Code: **E3810** Generic Name: **rabeprazole** Product Name: **Pariet/AcipHex**

Indications / Drug class: Proton pump inhibitor

In-house

Development Code: **E6007**

Indications / Drug class: Ulcerative colitis treatment / integrin activation inhibitor		In-house	
Description: A compound with a novel mechanism of action that is believed to suppress the adhesion and infiltration by multiple leukocyte types by inhibiting integrin activation. Development is conducted jointly with the University of Tsukuba as an industry-academia practical application project under the Japan Science and Technology Agency.			
○ Ulcerative colitis	Study 201	JP: PII	Development conducted by EA Pharma
			Oral

Development Code: **E6130**

○ Inflammatory bowel disease		JP: PI	In-house (development conducted by EA Pharma)
			Oral